Maria M Rubinstein

6PUBLICATIONS
61CO-AUTHORS
Predictive and prognostic markersMolecular targetsCell physiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Apr 22, 2025
ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma.

Joyce F Liu, Nicoletta Colombo, Amit M Oza

|Nov 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.

Angela K Green, Qin Zhou, Alexia Iasonos

|Jul 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles.

Beryl L Manning-Geist, Ying L Liu, Kelly A Devereaux

|Mar 05, 2020
Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's Witness.

Maria M Rubinstein, Cheryl Goss, Scott T Avecilla

|Dec 28, 2019
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.

Maria M Rubinstein, David M Hyman, Imogen Caird

Pageof 1

Frequent Collaborators

3 joint publications

Britta Weigelt

3 joint publications

Qin Zhou

3 joint publications

Pier Selenica

3 joint publications

Alexia Iasonos